In 2020, the company established the Pharmaceutical Research Institute, covering an area of 2750 square meters, aiming at "building high-quality CMC and CDMO drug research and development platform" as a high-level laboratory, positioning itself as one of the top 10 drug research and development platforms in Jiangsu Province, committed to providing high-end API and intermediates with high technology content, high quality and low price to domestic and foreign customers. At present, four API projects have entered the approval stage, and high-end API such as monkeypox virus specific drug "Tecoveri" and cystic fibrosis drug "Lumacato" have been successfully developed.
The analysis and testing laboratory is located on the second floor of the R&D building, covering an area of 480 square meters.
The synthesis laboratory is distributed on the first and third floors of the R&D building, covering an area of 900 square meters.
